Cambridge Healthtech Institute’s Inaugural
Biologics for Autoimmune Diseases
Emerging Targets, Therapeutic Strategies and Product Formats for a Growing Market
Part of the Tenth Annual PEGS: the essential protein engineering summit
May 5-6, 2014 | Seaport World Trade Center| Boston, MA
The specificity, efficacy and safety profiles of biologics have traditionally made them good candidates for the treatment of autoimmune diseases. Emerging genetic understandings of the mechanisms of these complex disorders are now being combined with exciting new therapeutic formats and strategies in a renewed wave of attention for the use of biotherapeutics in this therapeutic area. Bispecific and combination therapeutics will provide improved efficacy by impacting multiple targets and processes. Development of biosimilars and biobetters in this space will build on the success of proven therapeutics, while new technologies will offer expanded options for the application of promising validated targets from the past that were not advanced to the market.
The inaugural Biologics for Autoimmune Diseases presents a focused meeting that will track current clinical progress in the major autoimmune diseases, and then offer an exciting exploration of ways in which the industry is applying new science and technology in the development of a next generation of effective and safe therapeutics. Set in the context of the 10th annual PEGS, attendees of this meeting will join more than 1,500 colleagues working in the fields of protein engineering and biologics development, offering unprecedented opportunities for networking and scientific collaboration.
PLENARY KEYNOTE SESSION
Harnessing the Patient’s Immune System to Combat Cancer
Bahija Jallal, Ph.D., Executive Vice President, MedImmune
Building One of the World’s Top Biotechnology Companies from the Ground Up: The Story of Regeneron
George D. Yancopoulos, M.D., Ph.D., President, Regeneron Laboratories; CSO, Regeneron Pharmaceuticals, Inc.
Biologics for Systemic Lupus Erythematosus
William Stohl, M.D., Ph.D., Professor, Medicine, Rheumatology, Keck School of Medicine, University of Southern California
Clinical Update of Secukinumab (Anti-IL-17) for Psoriasis, RA and Ankylosing Spondilitis
Christian Antoni, M.D., Ph.D., Vice President, Senior Global Program Head, Integrated Hospital Care Franchise, Novartis Pharmaceuticals Corporation
Clinical Update of MEDI 551 (Anti-CD19 Antibody) for Autoimmune Disease
Ronald Herbst, Ph.D., Senior Director, Autoimmune Diseases, MedImmune
IL-1a/b DVD-Ig™: From Design to Clinic for Autoimmune Indications
Tariq Ghayur, Ph.D., Senior Research Fellow, AbbVie
Cytokine Modulation by Protein Therapeutics in Anterior and Posterior Ocular Disorders
Eric Furfine, Ph.D., President, R&D, Eleven Biotherapeutics
Development of a Human IgG4 Bispecific Antibody for Dual Targeting of IL-4 and IL-13 Cytokines
Lawren Wu, Ph.D., Senior Scientist, Immunology, Genentech, Inc.
Biology and Mechanism of Action for B Lymphocyte-Targeting DART Bispecifics for Autoimmune Disorders
Paul Moore, Ph.D., Vice President, Cell Biology & Immunology, Macrogenics
XmAb5871: An FcgRIIb-Enhanced Anti-CD19 Antibody for Nondepleting B Cell Inhibition
John Desjarlais, Ph.D., Vice President, Research, Xencor
mRNA-Engineered Mesenchymal Stem Cells as Targeted Drug Factories
Oren Levy, Ph.D., Instructor, Medicine, Harvard Medical School
AVX-470: An Oral Anti-TNF Antibody for Inflammatory Bowel Disease
Barbara S. Fox, Ph.D., CEO, Avaxia Biologics, Inc.
SOBI002: Small Affibody-ABD Fusion Protein Targeting Complement Factor C5 as a Next-Generation Biologic for Autoimmune Disease
Patrik Strömberg, Ph.D., Principal Scientist, Drug Design and Development, Swedish Orphan Biovitrum (Sobi), Sweden
Strategies Underlying Tolerance Induction with Antibodies as Combination Therapy
Herman Waldman, Ph.D., Emeritus Professor, Pathology, Therapeutic Immunology Group, Sir William Dunn School of Pathology, University of Oxford, United Kingdom
Antigenic Liposomes Displaying CD22 Ligands Induce Antigen-Specific B Cell Apoptosis
Matthew Macauley, Ph.D., Researcher, Paulson Laboratory, Chemical Physiology, The Scripps Research Institute
The MCAM/Laminin 411 Interaction Provides a TH17 Specific Mechanism for T Cell Entry into the CNS
Ken Flanagan, Ph.D., Senior Scientist, Cell Biology, Prothena Biosciences